Drugs

, Volume 67, Issue 16, pp 2355–2382

Multidrug-Resistant Streptococcus pneumoniae Infections

Current and Future Therapeutic Options
  • Françoise Van Bambeke
  • René R. Reinert
  • Peter C. Appelbaum
  • Paul M. Tulkens
  • Willy E. Peetermans
Review Article

DOI: 10.2165/00003495-200767160-00005

Cite this article as:
Van Bambeke, F., Reinert, R.R., Appelbaum, P.C. et al. Drugs (2007) 67: 2355. doi:10.2165/00003495-200767160-00005

Abstract

Antibacterial resistance in Streptococcus pneumoniae is increasing worldwide, affecting principally β-lactams and macrolides (prevalence ranging between ≈1% and 90% depending on the geographical area). Fluoroquinolone resistance has also started to emerge in countries with high level of antibacterial resistance and consumption. Of more concern, 40% of pneumococci display multi-drug resistant phenotypes, again with highly variable prevalence among countries.

Infections caused by resistant pneumococci can still be treated using first-line antibacterials (β-lactams), provided the dosage is optimised to cover less susceptible strains. Macrolides can no longer be used as monotherapy, but are combined with β-lactams to cover intracellular bacteria. Ketolides could be an alternative, but toxicity issues have recently restricted the use of telithromycin in the US. The so-called respiratory fluoroquinolones offer the advantages of easy administration and a spectrum covering extracellular and intracellular pathogens. However, their broad spectrum raises questions regarding the global risk of resistance selection and their safety profile is far from optimal for wide use in the community. For multi-drug resistant pneumococci, ketolides and fluoroquinolones could be considered. A large number of drugs with activity against these multi-drug resistant strains (cephalosporins, carbapenems, glycopeptides, lipopeptides, ketolides, lincosamides, oxazolidinones, glycylcyclines, quinolones, deformylase inhibitors) are currently in development. Most of them are only new derivatives in existing classes, with improved intrinsic activity or lower susceptibility to resistance mechanisms. Except for the new fluoroquinolones, these agents are also primarily targeted towards methicillin-resistant Staphylococcus aureus infections; therefore, demonstration of their clinical efficacy in the management of pneumococcal infections is still awaited.

Supplementary material

40265_2012_67162355_MOESM1_ESM.pdf (145 kb)
Supplementary material, approximately 149 KB.

Copyright information

© Adis Data Information 2007

Authors and Affiliations

  • Françoise Van Bambeke
    • 1
  • René R. Reinert
    • 2
  • Peter C. Appelbaum
    • 3
  • Paul M. Tulkens
    • 1
  • Willy E. Peetermans
    • 4
  1. 1.Unité de Pharmacologie Cellulaire et MoléculaireUniversité Catholique de LouvainBrusselsBelgium
  2. 2.Institute for Medical Microbiology, National Reference Center for StreptococciUniversity Hospital (RWTH)AachenGermany
  3. 3.Department of PathologyHershey Medical CenterHersheyUSA
  4. 4.Department of Internal Medicine-Infectious DiseasesKatholieke Universiteit Leuven, University Hospital GasthuisbergLeuvenBelgium

Personalised recommendations